

# 26S Proteasome [Ub-VS treated]

Proteasome



Cat. No. 65-1020-010

Lot. No. 30189

Quantity: 10 µg

Storage: -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS Page 1 of 2

## Background

The ubiquitin–proteasome system (UPS) targets selected proteins for degradation by the 26S proteasome. The initial steps in this pathway generate proteins that are covalently tagged with a polyubiquitin chain that is then recognized by ubiquitin receptors of the 26S proteasome. This is a large complex composed of a 20S catalytic core particle and two 19S regulatory particles (Kok, *et al.*, 1993) that catalyse the final step in the pathway. While the 20S particle is composed of a catalytic chamber for protein degradation, collectively the proteins that comprise the 19S particle perform several proteasomal functions that include recognition of ubiquitylated substrates, cleavage of the polyubiquitin chain for ubiquitin recycling, control of access to the 20S proteolytic chamber, and substrate unfolding and subsequent translocation into the 20S core particle for degradation (Boehringer, *et al.*, 2012). Mammalian proteasomes are associated with three DUBs: USP14, UCHL5 (UCH37) and RPN11 (POH1). UCHL5 and USP14 reside on the regulatory particle and remove ubiquitin from the substrate before substrate degradation whereas RPN11's activity is delayed until the proteasome is committed to degrading the substrate (Lee, *et al.*, 2010). The DUB activity of USP14 is known to be activated by proteasomes.

The 26S proteasome preparation in this product was prepared using the

Continued on page 2

## Physical Characteristics

**Species:** human

**Source:** transformed HEK293 cells

**Quantity:** 10 µg

**Concentration:** 0.2 mg/ml

**Formulation:** 50 mM Tris/HCl pH7.4, 10% glycerol, 1 mM ATP

**Molecular Weight:** ~2500 kDa

**Stability/Storage:** 12 months at -70°C; avoid multiple freeze/thaw cycles


## Protein Sequence:

The 26S proteasome preparation was prepared using the same protocol as described in Wang *et al.* (2007). Please refer to Wang *et al.* (2007) for a breakdown of the proteasome subunits and other components identified from the purified complex. The 26S proteasome-associated DUB activity was removed through washing and treatment with ubiquitin–vinylsulphone (Ub–VS) which forms an adduct with the active site cysteine in DUBs of the thiol protease class (Lee, *et al.*, 2010).

## Quality Assurance

### Purity:

4-12% gradient SDS-PAGE  
InstantBlue™ staining  
Lane 1: MW markers  
Lane 2: 3 µg 26S Proteasome  
[Ub-VS treated]



### Protein Identification:

The 26S proteasome preparation was prepared using the same protocol as described in Wang *et al.* (2007). Upon separation by 1D SDS-PAGE, the overall gel protein staining pattern of the purified 26S proteasome complex was visually and qualitatively very similar to that reported in Wang *et al.* (2007), Figure 1D.

Continued on page 2



www.ubiquigent.com  
Dundee, Scotland, UK

### ORDERS / SALES SUPPORT

International: +1-617-245-0020  
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)  
Email: sales.support@ubiquigent.com

### UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)  
US/Canada: +1-617-245-0020 (9AM-5PM UTC)  
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

# 26S Proteasome [Ub-VS treated]

## Proteasome

Cat. No. 65-1020-010

Lot. No. 30189

Quantity: 10 µg

Storage: -70°C



FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS Page 2 of 2

## Background

Continued from page 1

same protocol as described in Wang *et al.* (2007). The 26S proteasome-associated DUB activity was removed through washing and treatment with ubiquitin-vinylsulphone (Ub-VS) which forms an adduct with the active site cysteine in DUBs of the thiol protease class (Lee, *et al.*, 2010).

## References:

Boehringer, J *et al.* (2012) Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation, *Biochemical J* **448**, 55-65.

Kok, K *et al.* (1993) A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme, *Proc Natl Acad Sci USA* **90**, 6071-6075.

Lee, BH *et al.* (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14, *Nature* **467**, 179-184.


Wang, X. *et al.* (2007) Mass spectrometric characterization of the affinity-purified human 26S proteasome complex, *Biochemistry* **46**, 3553-3565.

## Quality Assurance

Continued from page 1

### 26S Proteasome Activity Assay:

26S proteasome proteolytic activity was validated by determining the increase in fluorescence measured as a result of the enzyme catalysed cleavage of fluorogenic peptide substrates (Suc-LLVY-AMC, Ac-RLR-AMC and Z-LLE-AMC) generating the peptide and AMC. Incubation of the substrate in the presence or absence of 26S proteasome was compared confirming the proteolytic activity of the 26S proteasome.



## Limited Use License

The Biotin AviTag™ technology is covered by U.S. Pat. Nos: 5,723,584; 5,874,239; 5,932,433; and 6,265,552 and includes any and all materials, methods, kits and related derivatives claimed by these patents. The purchase of the UBIQUIGENT's AviTagged products confers to the purchaser the limited right to use the AviTag™ technology for research use.

Commercial use of the AviTag™ technology to manufacture a commercial product, or use of the AviTag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays. Users desiring a commercial license should contact Avidity, LLC in the US @ 720-859-6111 or by email to Lansing@avidity.com.



www.ubiquigent.com  
Dundee, Scotland, UK

## ORDERS / SALES SUPPORT

International: +1-617-245-0020  
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)  
Email: sales.support@ubiquigent.com

## UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)  
US/Canada: +1-617-245-0020 (9AM-5PM UTC)  
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0